SAB Biotherapeutics Statistics

Total Valuation

SABS has a market cap or net worth of $248.07 million. The enterprise value is $157.43 million.

Market Cap	248.07M
Enterprise Value	157.43M

Important Dates

The next estimated earnings date is Tuesday, May 12, 2026, before market open.

Earnings Date	May 12, 2026
Ex-Dividend Date	n/a

Share Statistics

SABS has 70.28 million shares outstanding. The number of shares has increased by 562.28% in one year.

Current Share Class	70.28M
Shares Outstanding	70.28M
Shares Change (YoY)	+562.28%
Shares Change (QoQ)	-38.36%
Owned by Insiders (%)	2.69%
Owned by Institutions (%)	26.84%
Float	48.11M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.11
P/TBV Ratio	1.64
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	36.94
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.46, with a Debt / Equity ratio of 0.04.

Current Ratio	9.46
Quick Ratio	9.13
Debt / Equity	0.04
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-203.41

Financial Efficiency

Return on equity (ROE) is 14.96% and return on invested capital (ROIC) is -32.53%.

Return on Equity (ROE)	14.96%
Return on Assets (ROA)	-28.20%
Return on Invested Capital (ROIC)	-32.53%
Return on Capital Employed (ROCE)	-30.19%
Weighted Average Cost of Capital (WACC)	7.52%
Revenue Per Employee	n/a
Profits Per Employee	$49,550
Employee Count	86
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +101.71% in the last 52 weeks. The beta is 0.61, so SABS's price volatility has been lower than the market average.

Beta (5Y)	0.61
52-Week Price Change	+101.71%
50-Day Moving Average	3.87
200-Day Moving Average	3.27
Relative Strength Index (RSI)	40.00
Average Volume (20 Days)	374,957

Short Selling Information

The latest short interest is 3.00 million, so 4.27% of the outstanding shares have been sold short.

Short Interest	3.00M
Short Previous Month	2.50M
Short % of Shares Out	4.27%
Short % of Float	6.24%
Short Ratio (days to cover)	4.51

Income Statement

Revenue	n/a
Gross Profit	-33.35M
Operating Income	-48.95M
Pretax Income	13.27M
Net Income	4.26M
EBITDA	-45.87M
EBIT	-48.95M
Earnings Per Share (EPS)	-$0.79

Full Income Statement

Balance Sheet

The company has $96.59 million in cash and $5.95 million in debt, giving a net cash position of $90.64 million or $1.29 per share.

Cash & Cash Equivalents	96.59M
Total Debt	5.95M
Net Cash	90.64M
Net Cash Per Share	$1.29
Equity (Book Value)	151.49M
Book Value Per Share	3.18
Working Capital	90.37M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$44.78 million and capital expenditures -$933,156, giving a free cash flow of -$45.71 million.

Operating Cash Flow	-44.78M
Capital Expenditures	-933,156
Depreciation & Amortization	3.08M
Net Borrowing	-418,412
Free Cash Flow	-45.71M
FCF Per Share	-$0.65

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

SABS does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-562.28%
Shareholder Yield	-562.28%
Earnings Yield	1.72%
FCF Yield	-18.43%

Analyst Forecast

The average price target for SABS is $10.75, which is 204.53% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$10.75
Price Target Difference	204.53%
Analyst Consensus	Strong Buy
Analyst Count	4
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on January 5, 2024. It was a reverse split with a ratio of 1:10.

Last Split Date	Jan 5, 2024
Split Type	Reverse
Split Ratio	1:10

Scores

Altman Z-Score	n/a
Piotroski F-Score	2